About a year ago more or less, there was, as I remembered, a press release saying something like that Abbott is dropping the license, but BOCX was offering the license for "free" to Abbott but that BOCX can withdraw the offer at anytime unless Abbott expressively renew it. This is a fairly standard thing it appears, as no one else is licensing. Since then I have not kept up with the news much, as I was into some other things. I would imaging that if since then Abbott did not expressively made any action to revere its dropping, there is no real relation there. Whether they can actually pull the pet thing off remains to be seen. It has some potential but it is a low price product area. Success there can build up some scientific justification data for use on humans. ROSG is also in the cancer diagnostics area using microRNA, although its stuff is very expensive, but its stuff do not need FDA approval. ROSG's stuff only need state (in the US) approvals. The era of easy venture capital investment money is no longer as it was in todays harsh economic condition. It is time to get out there and do hard selling.
